Sitryx

OverviewSuggest Edit

Sitryx is a biopharmaceutical company focused on regulating cell metabolism. It develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.
TypePrivate
Founded2018
HQOxford, GB
Websitesitryx.com

Latest Updates

Employees (est.) (Oct 2021)31
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sitryx

Neil Weir

Neil Weir

CEO
Jonathan Senior

Jonathan Senior

CFO
Iain Kilty

Iain Kilty

CSO
Show more

Sitryx Office Locations

Sitryx has offices in Oxford and London
Oxford, GB (HQ)
Magdalen Centre, Robert Robinson Ave
London, GB
71 Kingsway, Holborn
Show all (2)

Sitryx Financials and Metrics

Summary Metrics

Founding Date

2018

Sitryx total Funding

$30 m

Sitryx latest funding size

$30 m

Time since last funding

3 years ago

Sitryx investors

Sitryx's latest funding round in October 2018 was reported to be $30 m. In total, Sitryx has raised $30 m
Show all financial metrics

Sitryx Revenue

Cash (31-Dec-2018)

10.2m
GBPFY, 2017FY, 2018

Cash

704.8k10.2m

Current Assets

770.3k10.6m
FY, 2017

Financial Leverage

-2.7 x
Show all financial metrics

Sitryx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Sitryx Online and Social Media Presence

Embed Graph

Sitryx News and Updates

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

INDIANAPOLIS and OXFORD, England, March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying...

Sitryx Frequently Asked Questions

  • When was Sitryx founded?

    Sitryx was founded in 2018.

  • Who are Sitryx key executives?

    Sitryx's key executives are Neil Weir, Jonathan Senior and Iain Kilty.

  • How many employees does Sitryx have?

    Sitryx has 31 employees.

  • Who are Sitryx competitors?

    Competitors of Sitryx include Ikena Oncology, iBio and Mersana Therapeutics.

  • Where is Sitryx headquarters?

    Sitryx headquarters is located at Magdalen Centre, Robert Robinson Ave, Oxford.

  • Where are Sitryx offices?

    Sitryx has offices in Oxford and London.

  • How many offices does Sitryx have?

    Sitryx has 2 offices.